Irinotecan in Treating Patients With Progressive or Recurrent Malignant Glioma

Part of paid clinical trials in Los Angeles, California.

Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study ID
NCT00003616
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Brain and Central Nervous System Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of irinotecan in treating patients who have progressive or recurrent malignant glioma.

Key Dates

Start date
Oct 22, 1998
Status verified
Jun 2018
Primary completion
May 17, 2002
Completion
Dec 20, 2005

Study Design

Primary purpose
TREATMENT

Locations (10)

FacilityCityStateZIPSite coordinators
Jonsson Comprehensive Cancer Center, UCLALos AngelesCalifornia90095-1781-
UCSF Cancer Center and Cancer Research InstituteSan FranciscoCalifornia94143-0128-
Dana-Farber Cancer InstituteBostonMassachusetts02115-
University of Michigan Comprehensive Cancer CenterAnn ArborMichigan48109-0752-
Children's Hospital of PittsburghPittsburghPennsylvania15213-
University of Pittsburgh Cancer InstitutePittsburghPennsylvania15213-3489-
Simmons Cancer Center - DallasDallasTexas75235-9154-
University of Texas - MD Anderson Cancer CenterHoustonTexas77030-4009-
University of Texas Health Science Center at San AntonioSan AntonioTexas78284-7811-
University of Wisconsin Comprehensive Cancer CenterMadisonWisconsin53792-6164-

Find similar trials in Los Angeles, CA

By research site
Jonsson Comprehensive Cancer Center, UCLA· Los Angeles, CAUCSF Cancer Center and Cancer Research Institute· San Francisco, CADana-Farber Cancer Institute· Boston, MAUniversity of Michigan Comprehensive Cancer Center· Ann Arbor, MIChildren's Hospital of Pittsburgh· Pittsburgh, PAUniversity of Pittsburgh Cancer Institute· Pittsburgh, PA

Related Studies